Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $18.75 Average Price Target from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been given an average rating of “Moderate Buy” by the nine research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $18.75.

A number of brokerages recently weighed in on LXEO. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 10th. Chardan Capital reiterated a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th.

Insider Transactions at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the transaction, the chief executive officer owned 377,817 shares in the company, valued at approximately $1,692,620.16. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the transaction, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 62,204 shares of company stock worth $280,089. 2.00% of the stock is owned by insiders.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Spruce Street Capital LP bought a new position in shares of Lexeo Therapeutics in the fourth quarter valued at about $1,738,000. Avoro Capital Advisors LLC acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth about $32,769,000. 683 Capital Management LLC lifted its stake in shares of Lexeo Therapeutics by 21.4% during the 4th quarter. 683 Capital Management LLC now owns 1,120,000 shares of the company’s stock worth $11,122,000 after buying an additional 197,338 shares during the last quarter. Bleakley Financial Group LLC bought a new stake in shares of Lexeo Therapeutics during the 1st quarter worth about $275,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Lexeo Therapeutics during the 4th quarter worth about $37,000. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Stock Up 2.9%

LXEO stock opened at $4.69 on Thursday. The company has a market cap of $368.26 million, a price-to-earnings ratio of -3.23 and a beta of 1.42. Lexeo Therapeutics has a twelve month low of $3.60 and a twelve month high of $10.99. The business has a 50 day moving average price of $4.84 and a two-hundred day moving average price of $6.20.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. On average, equities research analysts anticipate that Lexeo Therapeutics will post -1.21 EPS for the current fiscal year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.